New Zealand commits US$59m to district hospital upgrade
This article was originally published in Clinica
Executive Summary
New Zealand has committed NZ$80m (US$59m) to upgrade one of its key district hospitals, the Taranaki Base Hospital (TBH) in New Plymouth. The five-year programme that is due to begin in “late 2009” will take place in three stages, the first of which will include the building of two new surgical theatres (finally the facility will have six new theatres) and a new inpatient block to increase the number of patients that can be treated. The first phase will also include the development of ambulatory services. The government will provide NZ$43m, with the Taranaki District Health Board providing the balance funds. The TBH is the main hospital of two that serve the district and boasts “some of the most modern facilities in the country”. It includes a renal unit (dialysis, haemodialysis and training in home dialysis) and a cardiology suite (diagnostics only). Acute care patients for either of these areas must travel to Auckland for specialist intensive care facilities in these fields.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.